Viva Questions & Answers: Human Experiments - Evaluation of Psychomotor Activity Using Card Sorting Test

SECTION 1: BASICS AND RATIONALE

• They represent a homogeneous baseline without confounding disease effects
• Ethical clearance is easier for Phase I studies in healthy subjects
• Drug effects on normal CNS function can be cleanly assessed
• Pharmacokinetics are predictable and unaltered by disease
• Results can be attributed solely to the drug

SECTION 2: MATERIALS AND PROCEDURE

• A standard deck of 52 playing cards
• A stopwatch or timer
• A flat surface / table
• Data recording sheet
• Baseline assessment forms / questionnaires (e.g., sedation scale, visual analog scale)
• The test drug and placebo (in randomized/crossover designs)

1. Baseline recording: The volunteer sorts the 52 cards into 4 piles based on suit (Hearts, Diamonds, Clubs, Spades) as fast as possible. The time taken (in seconds) and number of errors are recorded. This is repeated 2-3 times to account for a learning effect and an average baseline is established.
2. Drug administration: The test drug is given orally (or by appropriate route) at the standard dose.
3. Post-drug testing: At appropriate time intervals (e.g., 30 min, 60 min, 90 min, 120 min after drug) the test is repeated and time + errors are recorded.
4. Analysis: Percentage change in sorting time and errors from baseline is calculated and compared.

SECTION 3: DESIGN AND CONTROLS

• Randomized: volunteers are randomly allocated to receive drug or placebo first
• Double-blind: neither the subject nor the observer knows which is the drug or placebo
• Placebo-controlled: a placebo arm eliminates the psychological effect of taking a pill (placebo effect)
• Crossover: same subject receives both drug and placebo on separate occasions (separated by a washout period), thus each subject serves as their own control, reducing inter-individual variability

• Eliminates inter-individual variability in CNS sensitivity and baseline performance
• Reduces the number of subjects required (each subject serves as their own control)
• Provides greater statistical power
• Controls for individual learning curves

• Healthy adults, 18-45 years
• Normal baseline psychomotor performance
• Written informed consent obtained
• No regular use of CNS-active drugs

• Pregnant or lactating females
• History of neurological or psychiatric disorders
• Current use of CNS depressants (alcohol, benzodiazepines, antidepressants)
• Hypersensitivity to the test drug
• Any systemic illness affecting cognition or motor function

• Written informed consent from each volunteer
• Approval from the Institutional Ethics Committee (IEC)
• Compliance with the Declaration of Helsinki principles
• Registration under the Schedule Y of the Drugs and Cosmetics Act (in India) / ICH GCP guidelines
• Provision for medical care in case of adverse events
• Right to withdraw at any time without penalty

SECTION 4: RESULTS AND INTERPRETATION

1. Time to sort (in seconds) - primary measure; increased time = impaired psychomotor performance
2. Number of errors - incorrect placement of cards; more errors = impaired cognition/attention
3. Optional: self-rated sedation score (e.g., Visual Analog Scale - VAS for sedation, Stanford Sleepiness Scale)

• Increased sorting time + increased errors post-drug = drug impairs psychomotor activity (CNS depressant effect) - e.g., diazepam, promethazine, alcohol
• Decreased sorting time + fewer errors post-drug = drug enhances performance (possible CNS stimulant) - e.g., low-dose caffeine
• No significant change = drug has no significant psychomotor effect (e.g., non-sedating antihistamines like fexofenadine)

• CNS depressants (positive controls): Diazepam (BZD), Lorazepam, Phenobarbitone, Alcohol, Promethazine (sedating antihistamine)
• Non-sedating antihistamines (to compare): Cetirizine, Fexofenadine - these should show minimal psychomotor impairment
• Anxiolytics: Buspirone (minimal impairment compared to BZDs)
• CNS stimulants: Caffeine, Modafinil

• Paired t-test: to compare pre- vs. post-drug values within the same subject
• ANOVA (repeated measures): when multiple time points are compared
• Mann-Whitney U test / Wilcoxon signed-rank test: if data is non-parametric
• Results are expressed as mean ± SEM with p-value; p < 0.05 is considered significant

SECTION 5: RELATED TESTS AND COMPARISONS

• The WCST (Grant & Berg, 1948) is a complex neuropsychological test assessing executive function, cognitive flexibility, and frontal lobe function. Cards are sorted by color, shape, or number, and the sorting rule changes without warning. It measures perseverative errors and set-shifting.
• The simple CST used in pharmacology practicals involves sorting a standard card deck by suit as fast as possible - it primarily measures psychomotor speed and attention, not executive function.
• WCST is used in neuropsychiatry; the simple CST is used in pharmacology human studies.

• Cognitive processing: recognizing card suit (attention, perception)
• Decision-making: allocating to the correct pile
• Motor execution: hand movements to place cards rapidly and accurately This integration of cognitive and motor processes makes it a valid measure of psychomotor activity. Drugs that impair attention, reaction time, or coordination will slow performance and increase errors.

SECTION 6: CNS PHARMACOLOGY CONCEPTS

• Sedation (decreased arousal)
• Impaired attention and memory (anterograde amnesia)
• Muscle relaxation (via spinal cord)
• Reduced reaction time and coordination All of these impair psychomotor performance in the CST.

• First-generation H1 blockers (chlorpheniramine, promethazine, diphenhydramine): lipophilic, cross the blood-brain barrier readily, block CNS H1 receptors (which normally promote wakefulness) → marked sedation and psychomotor impairment → significantly increase CST sorting time
• Second-generation H1 blockers (cetirizine, loratadine, fexofenadine): less lipophilic (except cetirizine at high doses), do not penetrate BBB as readily → minimal CNS sedation → minimal or no psychomotor impairment in CST
• This distinction is clinically important for patients who drive or operate machinery

SECTION 7: REGULATORY AND ETHICAL ASPECTS

• Nature and purpose of the study
• Procedures involved and time commitment
• Potential risks and benefits
• Confidentiality assurance
• Right to withdraw without consequences
• Contact details of the investigator and ethics committee
• In India, must comply with ICMR Guidelines and Schedule Y of Drugs & Cosmetics Act 1940

1. Respect for persons (Autonomy): Informed consent; protection of vulnerable groups
2. Beneficence: Maximize benefits, minimize harm
3. Justice: Fair selection and distribution of research burden and benefits

SECTION 8: SOURCES OF ERROR AND LIMITATIONS

1. Practice effect: must be controlled by pre-training sessions
2. Motivation variability: a bored or less motivated volunteer may perform poorly regardless of drug
3. Ceiling effect: highly practiced subjects may show no room for improvement; floor effect may prevent detection of impairment
4. Anxiety: baseline anxiety can affect performance (account for with questionnaires)
5. Time of day: circadian variation in alertness can influence results; all tests should be conducted at the same time
6. Placebo effect: a subject expecting sedation may perform poorly even with placebo - controlled by blinding
7. Inter-individual variability: differences in CNS sensitivity, age, weight, and prior drug use
8. Drug-food interactions: food can affect drug absorption; standardize fasting/food intake

SECTION 9: CLINICAL SIGNIFICANCE

• Provides data for drug labeling and package insert warnings (e.g., "Do not drive")
• Supports comparison of new drugs (e.g., non-sedating antihistamines) vs. older agents
• Assists in fitness-to-work/fitness-to-drive evaluations
• Helps establish safe dosing intervals (especially for shift workers, pilots, surgeons)
• Regulatory authorities (FDA, CDSCO) may require psychomotor testing data before drug approval

• Antihistamines: Established that second-generation agents (loratadine, fexofenadine) are significantly safer than first-generation agents for patients who drive
• Benzodiazepines vs. buspirone: Buspirone shown to have less psychomotor impairment compared to diazepam - supported its use where sedation is undesirable
• Z-drugs (zolpidem, zaleplon): Next-morning psychomotor impairment documented, leading to labeling changes and lower recommended doses (especially in women)
• Pregabalin/Gabapentin: Psychomotor testing helped establish dosing limits in outpatient settings

Viva Questions & Answers: Human Experiments - Evaluation of Analgesic Activity Using BP Cuff Inflation Method (Ischemic Pain Model)

SECTION 1: INTRODUCTION AND RATIONALE

• Increases the pain threshold (time to first pain perception)
• Increases the pain tolerance (time to maximum tolerable pain)
• Reduces pain intensity scores on subjective rating scales ...compared to placebo, in a controlled human pain model.

1. Minimal tissue damage - ischemia resolves completely after cuff deflation; no permanent injury
2. Correlation between stimulus strength and pain intensity - prolonged ischemia = greater pain
3. Stability over time - reproducible pain responses in the same subject on repeat testing
4. Sensitivity to analgesics - reliably detects pharmacological analgesia, especially from opioids
5. Clinical relevance - ischemic muscle pain closely resembles clinical ischemic pain (e.g., angina, claudication, post-surgical deep pain), making it more translationally valid than superficial pain models

• Mediated by A-delta (fast) and C fibers (slow) from muscle nociceptors
• Driven by accumulation of pain-producing metabolites (bradykinin, lactate, potassium ions, H⁺, adenosine) under ischemic conditions
• More similar to clinical pain compared to superficial cutaneous pain models
• Particularly sensitive to opioid analgesics

• The ischemic model produces deep somatic pain which more closely resembles the type of pain opioids are used clinically to treat (post-surgical, cancer, visceral)
• Opioids are more effective in the ischemic model than in superficial/cutaneous pain models
• The submaximal effort tourniquet test (SETT) - a variant of this model - has been validated specifically for detecting opioid analgesia at sub-analgesic doses
• Electrical models primarily test cutaneous sharp pain (A-delta), while ischemia activates both A-delta and C-fiber nociceptors more similarly to clinical states

SECTION 2: MATERIALS AND PROCEDURE

• Sphygmomanometer (mercury or aneroid) with standard BP cuff
• Stopwatch/timer
• Visual Analog Scale (VAS) for pain (0-100 mm or 0-10 cm scale)
• Numerical Rating Scale (NRS) for pain intensity
• Handgrip dynamometer (for the Submaximal Effort Tourniquet Test variant)
• Data recording sheets
• Test drug and matched placebo
• Safety monitoring equipment (pulse oximetry, resuscitation ready)

1. Obtain written informed consent; screen for inclusion/exclusion criteria
2. Seat the volunteer comfortably; ensure rest for 10-15 minutes before baseline testing
3. Measure baseline blood pressure (systolic BP)

• The cuff is inflated to suprasystolic pressure (as above)
• The volunteer then performs standardized handgrip exercises (e.g., squeezing a dynamometer to 75% of maximal grip strength every 2 seconds for 20-30 squeezes)
• This exhausts local muscle oxygen faster, intensifying ischemic metabolite production and producing pain more quickly and reliably
• The SETT is significantly more sensitive to opioid analgesics at low doses than simple cuff inflation alone
• Tourniquet time and cumulative analgesia scores were validated as outcome measures by Posner et al. (1984)

• Nerve ischemia and neuropraxia (temporary motor and sensory nerve dysfunction)
• Significant muscle damage and potential rhabdomyolysis (with very prolonged occlusion)
• Petechiae or bruising under the cuff

SECTION 3: OUTCOME MEASURES

1. Pain Threshold Time (T₁) - in seconds
2. Pain Tolerance Time (T₂) - in seconds
3. Tolerance/Threshold ratio (T₂/T₁) - a derived measure of the pain window
4. Visual Analog Scale (VAS) score at various time points (0 = no pain, 100 mm = worst imaginable pain)
5. Numerical Rating Scale (NRS) - 0-10 scale at threshold and tolerance
6. Total Pain Relief (TOTPAR) - area under the time-pain relief curve, used to assess overall analgesic effect
7. Sum of Pain Intensity Differences (SPID) - summation of pain intensity differences from baseline at multiple time points
8. Time to first pain relief (useful for comparative analgesic studies)

• Left end: "No pain at all" (0)
• Right end: "Worst imaginable pain" (100 mm)

• Percentage increase in pain threshold: [(Post-drug T₁ - Pre-drug T₁) / Pre-drug T₁] × 100
• Percentage increase in pain tolerance: [(Post-drug T₂ - Pre-drug T₂) / Pre-drug T₂] × 100
• Analgesic activity is confirmed if post-drug T₁ and/or T₂ are significantly greater than pre-drug values (and than placebo values in blinded designs)
• Area under the time-effect curve (AUC of tolerance time vs. clock time) can also be compared

SECTION 4: STUDY DESIGN AND ETHICS

• Randomized: volunteers allocated randomly to drug or placebo sequence
• Double-blind: neither the volunteer nor the investigator/assessor knows which treatment is administered
• Placebo-controlled: eliminates expectation/placebo analgesia effects
• Crossover: the same volunteer receives both drug and placebo on different occasions (separated by an adequate washout period), reducing inter-individual variability and the number of subjects required
• Each subject serves as their own control - key advantage because pain sensitivity varies greatly between individuals

• Healthy adults (18-45 years)
• Normal baseline pain threshold and tolerance (pre-screened)
• Normal cardiovascular status and upper limb vasculature
• Written informed consent
• Able to understand and comply with the protocol

• Pregnant or lactating females
• History of cardiovascular disease, peripheral vascular disease, or Raynaud's phenomenon
• Chronic pain conditions or recent use of analgesics (within 48 hours - 5 half-lives)
• Sickle cell disease or any clotting disorder
• Current use of anticoagulants, NSAIDs, opioids, or other CNS-active drugs
• Alcohol or substance use disorder
• Subjects with very low or very high baseline pain tolerance (extremes may mask drug effect)
• Allergy/hypersensitivity to the test drug

• Written informed consent detailing all procedures, risks, and the right to withdraw
• Institutional Ethics Committee (IEC) approval
• Compliance with the Declaration of Helsinki (WMA)
• In India: registration with CDSCO and compliance with Schedule Y of the Drugs and Cosmetics Act and ICMR Ethical Guidelines for Biomedical Research on Human Participants
• Safety monitoring: a physician present; emergency drugs and resuscitation equipment available
• Pre-defined safety cut-off time (maximum 15-20 minutes) to prevent tissue injury
• No financial coercion of volunteers

SECTION 5: PHYSIOLOGY AND PHARMACOLOGY

1. Potassium ions (K⁺) - released from ischemic muscle cells; directly activate nociceptors
2. Bradykinin - generated from kininogens via kallikrein activation; potent nociceptor activator
3. Lactic acid / H⁺ ions - from anaerobic metabolism; activate ASIC (acid-sensing ion channels) on nociceptors
4. Adenosine - activates P1 receptors on nociceptors
5. Prostaglandins - released from ischemic tissue; sensitize nociceptors (peripheral sensitization)
6. Serotonin - released from platelets; activates and sensitizes C-fiber nociceptors

1. Peripheral sensitization: Algogenic metabolites activate/sensitize free nerve endings (Group III Aδ and Group IV C fibers) in ischemic muscle
2. Primary afferents: Nociceptive signals travel via Aδ and C fibers to the dorsal horn of the spinal cord (synapse in laminae I, II, V)
3. Spinal cord: Glutamate (AMPA/NMDA receptors) and Substance P (NK-1 receptors) mediate synaptic transmission; second-order neurons cross in the anterior commissure
4. Ascending tracts: Pain signals ascend via the spinothalamic tract (lateral - pain/temperature) and spinoreticular tract
5. Thalamus: Relay in the ventroposterolateral (VPL) nucleus; also reticular formation (arousal/affect)
6. Cortex: Somatosensory cortex (SI, SII) - localization and intensity; Anterior cingulate cortex - affective/emotional component; Insular cortex - integration

• Presynaptically: Decrease Ca²⁺ influx → reduce release of Substance P and glutamate from primary afferents
• Postsynaptically: Increase K⁺ conductance → hyperpolarize and inhibit second-order neurons

• Activate descending inhibitory pathways (periaqueductal gray → rostral ventromedial medulla → dorsal horn)
• Release of endogenous serotonin and noradrenaline in the dorsal horn

• Peripheral effect: Reduced prostaglandin synthesis → decreased peripheral sensitization of nociceptors → raised pain threshold
• Central effect: Inhibition of spinal COX-2 → reduced central sensitization; some NSAIDs also inhibit spinal prostaglandin synthesis
• In the ischemic model, NSAIDs have weaker analgesic effect than opioids because the dominant pain mediators (K⁺, bradykinin, lactic acid, adenosine) are not prostaglandin-dependent
• Important: The classical submaximal effort tourniquet test (Posner, 1984) showed opioids significantly increased tolerance time but aspirin and indomethacin did NOT - demonstrating the model's selectivity for opioid-type analgesia

• Periaqueductal gray (PAG) matter - major site of opioid-mediated descending inhibition
• Rostral ventromedial medulla (RVM) - relay for descending inhibitory signals to dorsal horn
• Dorsal horn - spinal inhibitory interneurons releasing enkephalins
• This system is the basis for placebo analgesia (which can be blocked by naloxone), stress-induced analgesia, and the mechanism of exogenous opioid drugs

• Lowering of the activation threshold of peripheral nociceptors by inflammatory mediators (bradykinin, prostaglandins, NGF)
• Manifests as primary hyperalgesia (increased pain sensitivity at the site of injury)
• Example: In ischemic model, early phase of pain is partly driven by peripheral sensitization

• Amplification of nociceptive processing in the dorsal horn and higher centers, driven by sustained nociceptive input
• NMDA receptor activation → wind-up phenomenon → increased excitability of spinal neurons
• Manifests as secondary hyperalgesia (increased pain beyond the injured area) and allodynia (pain from normally non-painful stimuli)
• Example: Prolonged cuff inflation leads to central sensitization, explaining escalating pain intensity

SECTION 6: DRUGS USED AND EXPECTED RESULTS

• Morphine (10 mg oral or 0.1-0.15 mg/kg IV): Strong positive control - reliably increases T₁ and T₂
• Codeine (60 mg oral): Weak opioid - detectable increase in tolerance time even at this dose
• Tramadol (100 mg oral): Mixed opioid/monoaminergic - positive result
• Pethidine (Meperidine): Opioid agonist - positive control

• Aspirin, Ibuprofen, Indomethacin - NSAIDs show minimal/no significant effect on ischemic pain threshold/tolerance
• This differential response helps validate the model's selectivity for opioids

• It may slightly increase pain tolerance (through anxiolysis/affective component suppression)
• It does not significantly increase pain threshold
• Any apparent increase in tolerance is due to reduction in the anxiety/fear component of pain, not true nociceptive analgesia This distinguishes it from true analgesics and illustrates the difference between pain threshold (nociceptive) and pain tolerance (affective/emotional component).

• Pain threshold time (T₁) increases significantly post-drug vs. pre-drug
• Pain tolerance time (T₂) increases significantly post-drug vs. pre-drug
• VAS scores at T₁ and T₂ decrease
• These changes should be statistically significant compared to the placebo session
• The magnitude of increase in T₁ and T₂ can be compared to a known analgesic (e.g., codeine) to establish relative potency

SECTION 7: COMPARISON WITH OTHER PAIN MODELS

SECTION 8: STATISTICS AND LIMITATIONS

• Paired t-test: Compare pre-drug vs. post-drug T₁ and T₂ within subjects
• Repeated measures ANOVA: For multiple time points post-drug
• Student's unpaired t-test / Mann-Whitney U: If comparing two groups
• Wilcoxon signed-rank test: If data is non-parametric
• Results expressed as mean ± SEM; p < 0.05 is considered statistically significant
• Area Under the Curve (AUC) analysis for time-effect relationship

1. Specificity for opioid analgesia: NSAIDs and other non-opioid analgesics show poor efficacy - limits use for screening non-opioid drugs
2. Practice effect: Repeated testing can lead to habituation or sensitization; must be controlled
3. Psychological variability: Pain tolerance is heavily influenced by motivation, anxiety, stoicism, and expectation - high inter-individual variability
4. Ceiling/floor effects: Very high or very low baseline tolerance may limit ability to detect drug effect
5. Cannot simulate chronic pain: Ischemic model produces only acute experimental pain; chronic pain mechanisms (central sensitization, neuroplasticity) are not captured
6. Not suitable for assessing topical or locally acting analgesics
7. Discomfort for volunteers: Despite reversibility, the test involves significant pain and requires highly motivated participants
8. Predictive validity is imperfect: Good sensitivity for opioids, but poor for NSAIDs and adjuvant analgesics; clinical translation is not always reliable

• Using an identical-looking placebo (same size, shape, color, taste as the drug)
• Double-blinding (neither the subject nor the assessor knows which treatment is being given)
• Including a placebo arm in the crossover design so that placebo effects can be measured and subtracted from the drug effect
• Randomization of the treatment sequence

SECTION 9: CLINICAL APPLICATIONS

• Provide Phase I evidence of analgesic efficacy before large-scale Phase II/III trials
• Support dose selection for subsequent clinical trials
• Enable comparison of relative analgesic potency between drugs (e.g., new opioid vs. morphine)
• Regulatory bodies (FDA, EMA, CDSCO) accept data from validated human pain models as part of the clinical development package for new analgesics
• Help establish warnings (e.g., "may impair driving" for opioids) based on psychomotor + analgesic testing together

• Morphine, codeine, oxycodone: Reliably increase tourniquet tolerance time - established as μ-opioid agonists with analgesic efficacy
• Tramadol: Analgesic effect confirmed in SETT, supporting its mixed opioid/noradrenergic mechanism
• Buprenorphine: Partial μ-agonist - analgesic effect demonstrable at low doses
• Aspirin / Indomethacin / NSAIDs: Consistently negative in the ischemic model - confirming the model's selectivity for opioid rather than anti-inflammatory analgesia (Posner, 1984)
• IV Lidocaine: Shown to reduce ischemic pain in healthy volunteers (Froelich et al., 2010 - PMC2951626)
• Naloxone: Reverses opioid-induced increase in tolerance time, validating opioid-receptor mediation

1. Step 1 - Non-opioid analgesics: Paracetamol (acetaminophen), NSAIDs (ibuprofen, diclofenac, naproxen), COX-2 selective inhibitors (celecoxib, etoricoxib)
2. Step 2 - Weak opioids: Codeine, tramadol, tapentadol (low dose)
3. Step 3 - Strong opioids: Morphine, oxycodone, fentanyl, hydromorphone, buprenorphine

• Antidepressants (amitriptyline, duloxetine) - neuropathic pain
• Anticonvulsants (gabapentin, pregabalin) - neuropathic pain
• Local anesthetics (lidocaine) - topical/regional
• Muscle relaxants (baclofen, cyclobenzaprine) - musculoskeletal pain
• Corticosteroids - inflammatory pain

Viva Questions & Answers: Human Experiments - Analgesic Activity Using Crown Cap AND BP Cuff Inflation Method (Combined Pain Models)

SECTION 1: OVERVIEW AND RATIONALE

1. Crown Cap Method - A surface mechanical pressure pain model producing superficial/cutaneous pain by pressing a serrated metal bottle crown cap against the finger pulp
2. BP Cuff Inflation Method - An ischemic pain model producing deep somatic pain by tourniquet occlusion of the arm

• Different classes of analgesics work preferentially on different types of pain
• NSAIDs/paracetamol are more effective in the crown cap (surface/inflammatory) model
• Opioids are more effective in the BP cuff (deep ischemic) model
• Using both models in the same experiment allows assessment of the spectrum of analgesic activity of a drug and helps characterize whether it acts more like a peripherally-acting or centrally-acting analgesic
• Together they provide a comprehensive pharmacological profile of the test drug

• Crown cap method: assesses effect on cutaneous mechanical pressure pain (more sensitive to peripherally acting analgesics like NSAIDs and paracetamol)
• BP cuff inflation: assesses effect on deep ischemic pain (more sensitive to centrally acting analgesics like opioids)

SECTION 2: CROWN CAP METHOD - DETAILS

• Produces superficial, cutaneous, sharp/pricking pain (mediated predominantly by Aδ fibers)
• Simulates the type of pain sensitive to NSAIDs, paracetamol, and other peripherally acting analgesics
• Simple, inexpensive, reproducible apparatus using widely available materials

• A standard metal bottle crown cap (21 serrations/teeth on the crimped edge) is fixed with the serrated edge facing upward inside a small holder/platform
• The volunteer's finger (typically the index or middle finger of the non-dominant hand) is placed with the pulp resting on the serrated crown cap
• A standardized weight or graded pressure is applied progressively on the dorsum of the finger, pressing the pulp onto the cap's serrated edge

1. The volunteer is seated comfortably; finger placed on the crown cap
2. A standard weight (starting at 0, increasing incrementally, e.g., 200g steps) is placed on the finger
3. The volunteer is asked to report the moment they first feel pain (not just pressure) - this is Pain Threshold (weight in grams or time in seconds)
4. The weight at which pain becomes unbearable is recorded as Pain Tolerance
5. Repeated 2-3 times to obtain a stable baseline (accounting for the practice/learning effect)

• Superficial cutaneous pain - sharp, pricking quality
• Mediated by Aδ (A-delta) fibers - fast pain, well-localized, sharp in character
• Some C-fiber activation at higher pressures (slow, burning quality)
• The pain mechanism involves:
  • Mechanical deformation of superficial skin nociceptors
  • At higher intensities, local tissue micro-trauma releases prostaglandins, bradykinin, and serotonin which sensitize nociceptors
• This is predominantly nociceptive pain without ischemia or significant inflammatory component (unlike the BP cuff model)
• Most sensitive to NSAIDs, paracetamol, local anesthetics

1. Sensitize nociceptors (peripheral sensitization) - lowering their activation threshold
2. Lower the pain threshold (primary hyperalgesia at the site)

• Preventing peripheral sensitization of nociceptors
• Raising the pain threshold in the crown cap model

1. Pain Threshold - the weight (in grams) or time (in seconds) at which the sensation changes from mere pressure to pain
2. Pain Tolerance - the weight (in grams) or time at which pain becomes unbearable/maximal tolerable
3. VAS score (Visual Analog Scale, 0-100 mm) - pain intensity at threshold and tolerance
4. Numerical Rating Scale (NRS) - 0-10 pain score
5. Percentage increase in pain threshold post-drug = primary efficacy measure

SECTION 3: BP CUFF INFLATION METHOD (RECAP AND COMPARISON)

• If a drug increases threshold/tolerance in both models → likely a centrally acting analgesic (e.g., opioid)
• If effect is only in crown cap → likely a peripheral/anti-inflammatory analgesic (e.g., NSAIDs)
• If effect is only in BP cuff → likely a centrally acting analgesic with opioid-type mechanism

1. BP cuff applied to the arm and inflated to 200 mmHg (suprasystolic) to cause complete arterial occlusion
2. Stopwatch started at the moment of inflation
3. Pain Threshold Time (T₁): time (seconds) when discomfort first becomes pain
4. Pain Tolerance Time (T₂): time (seconds) when pain becomes unbearable
5. Cuff deflated immediately at T₂ or at the 20-minute safety cut-off
6. Test repeated post-drug at appropriate intervals (based on drug's Tmax)
7. Optionally, the Submaximal Effort Tourniquet Test (SETT) variant includes handgrip exercises to accelerate ischemia

SECTION 4: COMBINED STUDY DESIGN

• At least 3 sessions per volunteer (drug A, drug B if comparative, and placebo) separated by adequate washout periods
• Each session includes both crown cap and BP cuff tests, conducted in a fixed order with rest periods between
• Randomization of the treatment allocation (Latin square design for multiple treatment groups)
• Time-matched testing post-drug to capture the pharmacokinetic peak effect (Tmax)

• Inter-individual variation in baseline pain sensitivity (crossover design)
• Placebo/expectation effects (double-blind, placebo arm)
• Carryover effects (washout period)

• The BP cuff test causes more intense, deep pain and requires full recovery (5-10 minutes after cuff deflation) before any other painful stimulus is applied
• A minimum of 15-20 minutes rest must be given between the two tests to prevent carry-over sensitization (central sensitization from the first pain test inflating the apparent effect of the second)
• Some protocols alternate the order across sessions to control for sequence effects
• The two tests should never be performed simultaneously

• Healthy adults, 18-45 years, either sex (or male-only in some protocols to avoid menstrual cycle variability)
• Normal baseline pain threshold and tolerance in both tests (pre-screening session required)
• Normal cardiovascular status and intact peripheral vasculature
• Intact skin on finger (for crown cap) and arm (for BP cuff)
• Written informed consent

• Pregnant or lactating women
• History of chronic pain, neuropathy, or vascular disease
• History of Raynaud's phenomenon or peripheral vascular disease
• Skin disease or lesions at the test sites
• Current use of analgesics, anticoagulants, or any CNS-active drugs (within 5 half-lives)
• Alcohol use within 24 hours of the test
• Allergy to the test drug
• Sickle cell disease
• Known sensitivity extremes (outliers excluded on pre-screening)

• Written informed consent from each volunteer (covering both test procedures and all associated discomfort)
• IEC (Institutional Ethics Committee) approval prior to study initiation
• Compliance with the Declaration of Helsinki
• In India: compliance with ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017) and Schedule Y of the Drugs and Cosmetics Act
• Right to withdraw at any time without penalty
• Safety cut-off time for BP cuff (20 min maximum); maximum pressure defined for crown cap
• Emergency medical support available
• Volunteer payment must not be coercive (reasonable compensation only)

SECTION 5: PAIN PHYSIOLOGY

1. Mechanonociceptors - respond to high-intensity mechanical stimuli (crown cap model - pressure)
2. Thermonociceptors - respond to extremes of temperature
3. Polymodal nociceptors (C-fiber nociceptors) - respond to mechanical, thermal, and chemical stimuli; activated in both models

• Crown cap predominantly activates Aδ fibers (sharp cutaneous pricking pain)
• BP cuff activates both Aδ (Group III muscle afferents) and C fibers (Group IV) → deep, aching, cramping pain

• Prostaglandins (PGE₂, PGI₂) - released from micro-traumatized tissue; peripheral sensitization
• Bradykinin - released from plasma kininogens; direct nociceptor activator
• Serotonin (5-HT) - released from platelets; activates C-fiber nociceptors
• Histamine - released from mast cells; activates nociceptors
• Substance P - local axon reflex release; vasodilation, neurogenic inflammation

• Potassium ions (K⁺) - directly activate nociceptors
• Lactic acid / H⁺ (protons) - activate ASIC (Acid-Sensing Ion Channels) on muscle afferents
• Bradykinin - potent activator of both Aδ and C fibers
• Adenosine - activates P1 (A1/A2) receptors on nociceptors
• Prostaglandins - sensitize nociceptors (contributing factor)
• ATP - activates P2X3 receptors on nociceptors

• Aδ fibers at 5-30 m/s → "first pain" (sharp, immediate)
• C fibers at 0.5-2 m/s → "second pain" (delayed, aching) ...to the dorsal root ganglion (DRG) and then to the dorsal horn of the spinal cord.

• Lamina I (Rexed): Aδ fibers (nociceptive specific neurons, NS)
• Lamina II (Substantia Gelatinosa): C fibers (modulation by interneurons)
• Lamina V: Wide Dynamic Range (WDR) neurons - convergence of somatic and visceral nociceptive input
• Neurotransmitters: Glutamate (AMPA/NMDA receptors) and Substance P (NK1 receptors)
• Second-order neurons cross via the anterior white commissure

• Lateral spinothalamic tract (pain, temperature) → contralateral VPL nucleus of thalamus
• Spinoreticular tract → reticular formation → arousal, autonomic responses
• Spinomesencephalic tract → PAG → descending inhibition

• Ventroposterolateral (VPL) nucleus → somatosensory cortex (SI, SII)
• Intralaminar nuclei → anterior cingulate, prefrontal cortex

• Primary somatosensory cortex (SI): Pain localization, intensity
• Secondary somatosensory cortex (SII): Pain discrimination
• Anterior cingulate cortex (ACC): Affective/emotional component of pain (suffering)
• Insula: Integration of pain with autonomic and emotional responses
• Prefrontal cortex: Cognitive modulation of pain (expectation, attention)

• Large diameter, myelinated fibers (Aβ) carrying touch/vibration signals → stimulate inhibitory interneurons in substantia gelatinosa → CLOSE the gate (inhibit pain transmission)
• Small diameter Aδ and C fibers (pain) → inhibit the inhibitory interneurons → OPEN the gate (facilitate pain transmission)

• Explains why rubbing an injured area (activating Aβ fibers) reduces pain (closes the gate) - a phenomenon relevant to understanding how the crown cap's pressure stimulus interacts with tactile input
• Explains the basis of TENS (Transcutaneous Electrical Nerve Stimulation) for pain relief
• Highlights the role of the CNS in modulating pain - important for understanding why psychological factors (anxiety, attention) affect pain threshold and tolerance in both test models

• Lowering of the activation threshold of peripheral nociceptors by inflammatory mediators (PGE₂, bradykinin, NGF)
• Manifests as primary hyperalgesia (increased sensitivity at the site of injury/stimulus)
• In the crown cap model: repeated application of the cap causes local release of prostaglandins → peripheral sensitization → lower pain threshold with repeat testing (must be controlled by rest periods)
• NSAIDs reverse peripheral sensitization by blocking prostaglandin synthesis

• Amplification of nociceptive processing in the dorsal horn, driven by sustained C-fiber input
• Mechanism: NMDA receptor activation → phosphorylation → increased excitability ("wind-up")
• Manifests as secondary hyperalgesia (pain in areas beyond the site of injury) and allodynia (pain from normally non-painful stimuli)
• In the BP cuff model: prolonged ischemia can produce central sensitization, explaining escalating pain intensity disproportionate to the ischemic stimulus
• Gabapentin, pregabalin, ketamine reduce central sensitization

SECTION 6: ANALGESIC PHARMACOLOGY

• Inhibit COX-1 and COX-2 (cyclooxygenase enzymes) → block conversion of arachidonic acid to prostaglandins (PGE₂, PGI₂, TXA₂, PGD₂)
• Peripheral effect: Reduced PGE₂ → prevents sensitization of nociceptors → raises pain threshold
• Central effect: Some spinal COX-2 inhibition → reduced central sensitization
• Additional effects: Some NSAIDs (e.g., ketorolac) have central anti-nociceptive activity

• Central COX inhibition (preferential inhibition of COX in the CNS, particularly a COX-3 variant)
• Serotonergic pathway: activates descending inhibitory serotonergic pathways (5-HT₃ antagonism at the spinal cord level)
• Endocannabinoid pathway: metabolized to AM404 (in the CNS), which activates CB₁ receptors and TRPV1 channels → central analgesia
• Weak peripheral anti-inflammatory effect (no significant peripheral COX inhibition at therapeutic doses)
• Net effect: predominantly central analgesic with minimal anti-inflammatory action at periphery
• Effective in crown cap model (via central mechanisms) but less so than NSAIDs for inflammatory pain

1. Non-selective COX-1 + COX-2 inhibitors:
   • Salicylates: Aspirin (irreversible), diflunisal
   • Propionic acid derivatives: Ibuprofen, naproxen, ketoprofen
   • Acetic acid derivatives: Indomethacin, diclofenac, ketorolac, etodolac
   • Fenamates: Mefenamic acid
   • Oxicams: Piroxicam, meloxicam (mild COX-2 preference)
2. Preferential COX-2 inhibitors:
   • Meloxicam, nimesulide, nabumetone
3. Selective COX-2 inhibitors (Coxibs):
   • Celecoxib, etoricoxib, parecoxib

• Salicylates, Propionic acids, Acetic acids, Fenamates, Oxicams, Pyrazolones (e.g., phenylbutazone), Coxibs

• Reduce nociceptor sensitization (especially in inflamed tissue)

• Pre-synaptic: Reduce Ca²⁺ influx → decreased release of Substance P and glutamate from primary afferents
• Post-synaptic: Increase K⁺ efflux → hyperpolarization → inhibit second-order neurons

• Activate Periaqueductal Gray (PAG) → disinhibit RVM (rostral ventromedial medulla) → activate descending serotonin/noradrenaline pathways → spinal cord inhibition
• Limbic system: reduces affective component of pain (anxiety, suffering)

1. Periaqueductal Gray (PAG) in the midbrain: receives inputs from frontal cortex, hypothalamus, and amygdala; activated by stress, opioids, and expectation (placebo). PAG neurons project to the RVM.
2. Rostral Ventromedial Medulla (RVM) (including nucleus raphe magnus): Projects to the dorsal horn via the dorsolateral funiculus (DLF). Contains:
   • "Off" cells: inhibit pain transmission (activated by opioids)
   • "On" cells: facilitate pain transmission
3. Locus Coeruleus (noradrenergic nucleus, pons): Projects to dorsal horn; releases noradrenaline → activates α₂ receptors → inhibits pain transmission
4. Dorsal horn: Descending serotonin (5-HT) and noradrenaline activate inhibitory interneurons (releasing enkephalins, GABA) in the substantia gelatinosa → inhibit primary afferent and second-order neuron transmission

• This system explains the mechanism of opioids (activate PAG/RVM "off" cells)
• Tramadol, SNRIs (duloxetine), TCAs (amitriptyline): augment descending noradrenergic/serotonergic inhibition
• Morphine acts at PAG, RVM, and dorsal horn simultaneously

SECTION 7: COMPARISON OF DRUGS IN BOTH MODELS

• Crown Cap model: Ibuprofen (400-600 mg oral) → significant increase in pain threshold and tolerance (↑T₁, ↑T₂) due to COX inhibition, prevention of peripheral nociceptor sensitization via prostaglandin blockade
• BP Cuff model: Ibuprofen → minimal or no significant effect on ischemic pain threshold/tolerance, because dominant ischemic mediators (K⁺, H⁺, bradykinin) are not prostaglandin-dependent
• Conclusion: Ibuprofen profile = peripheral/anti-inflammatory analgesic; effective for surface/inflammatory pain, not deep ischemic pain

• Crown Cap model: Morphine (10 mg oral/parenteral) → moderate increase in pain threshold and tolerance (some effect on cutaneous pain via supraspinal mechanisms, but less than on deep pain)
• BP Cuff model: Morphine → significant and pronounced increase in T₁ and T₂; this is the model in which morphine is most demonstrably effective
• Conclusion: Morphine profile = central analgesic (opioid); most effective for deep ischemic pain; confirms μ-opioid receptor-mediated mechanism

• Crown Cap model: Paracetamol (1g oral) → mild to moderate increase in pain threshold (central COX/serotonergic mechanisms); less potent than NSAIDs for inflammatory pain
• BP Cuff model: Paracetamol → minimal effect on ischemic pain tolerance time (as confirmed in experimental studies; Olesen et al., 2012, note that paracetamol's effect is "difficult to detect" in experimental pain models without neurophysiological methods)
• Conclusion: Paracetamol = central analgesic with weak peripheral activity; works for mild-moderate pain, less effective for intense deep ischemic pain

SECTION 8: PAIN SCALES AND STATISTICAL ANALYSIS

• Paired t-test: Compare pre- vs. post-drug values (T₁ and T₂) within the same subject (intra-group analysis)
• Repeated measures ANOVA (RM-ANOVA): For multiple time-point comparisons post-drug (30, 60, 90, 120 min), followed by post-hoc Tukey or Bonferroni test
• Two-way ANOVA: Compare drug effect across both models simultaneously (factor 1: drug/placebo; factor 2: pain model type)
• Mann-Whitney U test / Wilcoxon Signed-Rank test: If data is non-parametric or skewed
• TOTPAR (Total Pain Relief) and SPID (Sum of Pain Intensity Differences): Derived parameters for overall analgesic effect over time
• Results expressed as mean ± SEM; p < 0.05 = statistically significant

SECTION 9: SOURCES OF ERROR AND LIMITATIONS

1. Practice/learning effect: Volunteers get better at enduring the cap with repeated exposures; must be pre-trained to baseline plateau
2. Skin variability: Differences in skin thickness, callus formation, finger size affect threshold; always use the same finger and same site
3. Orientation of cap: The cap must always be placed identically (same number of serrations in contact); standardize placement with a jig or holder
4. Applied weight variability: Must use calibrated weights; hand-pressing is not reproducible
5. Motivation and stoicism: Volunteers may "push through" pain for various reasons; use standardized verbal cues
6. Anxiety at first exposure: Pre-test familiarization session essential
7. Skin temperature: Cooler skin has lower pain threshold for pressure; control ambient temperature

1. Predictive validity: Experimental pain models (especially for superficial pain) do not always accurately predict clinical analgesic efficacy in disease states
2. Healthy volunteer vs. patient: Pathological pain in patients involves peripheral and central sensitization, neuroplasticity, and psychological factors not present in healthy volunteers - drug effects may differ
3. Cannot model chronic pain: Both models produce only acute experimental pain
4. Ethical ceiling: Safety cut-offs and ethical limits prevent reaching extreme pain intensities
5. Selectivity: The crown cap model is relatively selective for NSAIDs/paracetamol; BP cuff for opioids - neither is a "universal" model for all analgesic classes
6. Gender differences: Women generally have lower pain thresholds and tolerances; must stratify or match by sex
7. Circadian variation: Pain sensitivity fluctuates across the day; always test at the same time

SECTION 10: CLINICAL AND REGULATORY SIGNIFICANCE

• Provides a pharmacological fingerprint of the test drug: is it acting peripherally (NSAID-like) or centrally (opioid-like)?
• Identifies the type of clinical pain the drug is best suited for
• Helps in dose optimization: different models may show optimal analgesic effect at different doses
• Enables relative potency comparisons vs. established drugs (aspirin, codeine equivalence)
• Reduces the number of Phase II trial designs needed by providing mechanistic data early
• Regulatory bodies (FDA, EMA, CDSCO) accept validated experimental pain model data as Phase I analgesic efficacy evidence

• The experiment deliberately inflicts pain on subjects who have no disease requiring treatment - no direct therapeutic benefit to the participant
• The primary beneficiary is society (future patients) and pharmaceutical knowledge
• This makes strict application of the Belmont principles (autonomy, beneficence, justice) especially important
• Autonomy: True informed consent is paramount - the volunteer must fully understand both the crown cap and BP cuff pain they will experience, and that withdrawal is unconditional
• Beneficence/Non-maleficence: Safety cut-offs for both methods, physician presence, emergency protocols
• Justice: Fair compensation without coercion; no targeting of economically vulnerable populations
• IRB/IEC oversight is non-negotiable; India's ICMR guidelines specifically address experimental pain studies in healthy volunteers

Viva Questions & Answers: Human Experiments - Effect of Propranolol on BP, HR, and Cardiac Workload Using Master's Two-Step Exercise Stress Test

SECTION 1: INTRODUCTION AND RATIONALE

1. Heart Rate (HR) - resting and post-exercise
2. Blood Pressure (BP) - systolic, diastolic, and pulse pressure
3. Cardiac Workload (Rate Pressure Product / Double Product) - an indirect index of myocardial oxygen demand

• During exercise, sympathetic activity surges massively, releasing noradrenaline and adrenaline → stimulating β₁ and β₂ adrenoceptors
• Propranolol competitively blocks these receptors; the higher the agonist concentration (as in exercise), the greater the degree of blockade (shifts dose-response curve to the right)
• At rest, basal sympathetic tone is low, so propranolol's effect is modest
• This demonstrates the concept of "state-dependence" or "use-dependent" pharmacology - drugs that work best when the system they modulate is most active
• Exercise also tests whether propranolol's anti-anginal benefit (reduced cardiac work during exertion) can be demonstrated in a healthy surrogate model

• Is simple, standardized, and reproducible - requires only a two-step platform
• Provides sub-maximal exercise - defined by standard tables based on the subject's age, sex, and body weight; avoids dangerous maximal exertion in healthy volunteers
• Is safe for use in a non-clinical pharmacology practical setting
• Requires no expensive equipment (treadmill, bicycle ergometer)
• Produces reliable, quantifiable increases in HR and BP that serve as measurable endpoints for drug effect
• Has been validated as a clinical cardiac stress test by Arthur M. Master (1968)

SECTION 2: MASTER'S TWO-STEP TEST - DETAILS

• Two wooden or solid steps, each 9 inches (approximately 22.5 cm) in height and at least 18 inches (45 cm) wide
• Total height climbed in each complete "trip" = 18 inches (up 9", up 9", down 9", down 9")
• A stopwatch or metronome to time the exercise
• Sphygmomanometer (mercury or aneroid)
• Stethoscope
• ECG machine (optional, for monitoring)

• Age (years)
• Sex (male or female)
• Body weight (in kg or lbs)

1. Obtain written informed consent; screen for inclusion/exclusion criteria
2. Seat volunteer at rest for 10-15 minutes; measure baseline resting HR and BP (3 readings, average)
3. Determine number of trips from Master's table based on age, sex, weight
4. Administer placebo (or drug, randomized) in a double-blind manner
5. Wait for appropriate time (Tmax of propranolol oral = 1-2 hours; for the experiment, usually 60-90 min post-dose)

• HR (by pulse rate for 15 seconds × 4, or by ECG)
• BP (systolic and diastolic) within 1-2 minutes post-exercise

1. Record post-exercise HR and BP at 1 min, 5 min, and 10 min recovery intervals

1. Resting HR (bpm) - pre-drug
2. Post-drug resting HR - 60-90 min after drug/placebo
3. Post-exercise HR - immediately after the two-step test (1 min, 5 min recovery)
4. Resting BP (systolic/diastolic) - pre and post-drug
5. Post-exercise systolic BP and diastolic BP (mmHg)
6. Pulse Pressure (PP) = Systolic BP - Diastolic BP
7. Rate Pressure Product (RPP) = HR × Systolic BP (at rest and post-exercise)
8. Percentage reduction in RPP by propranolol vs. placebo = primary efficacy measure

SECTION 3: RATE PRESSURE PRODUCT (CARDIAC WORKLOAD)

RPP = Heart Rate (HR, beats/min) × Systolic Blood Pressure (SBP, mmHg)

• At rest: normal RPP = 7,000-12,000 mmHg·bpm
• RPP > 20,000 = significant cardiac workload; may provoke angina in susceptible individuals
• RPP > 30,000 = high cardiac stress
• Propranolol reduces RPP by decreasing both HR (negative chronotropy) and SBP during exercise → reduces myocardial oxygen demand → prevents exercise-induced angina
• Used to set safe exercise targets for cardiac rehabilitation patients
• Monitors efficacy of anti-anginal drugs

1. Increased heart rate (HR) - sympathetic activation → β₁ stimulation → tachycardia; more beats per minute = more oxygen consumed per unit time
2. Increased myocardial contractility (inotropy) - β₁ stimulation increases force of contraction → more energy (ATP/O₂) required per beat
3. Increased afterload - exercise raises systolic BP → ventricle must generate more pressure to eject blood → increased wall stress (LaPlace: wall stress = P × r / 2t)
4. Increased preload - increased venous return during exercise increases end-diastolic volume → Starling mechanism → increased stroke volume but also increased wall tension
5. Increased metabolic demand of cardiac muscle itself from higher rate of contraction

• Heart rate (most important determinant)
• Myocardial wall tension (= afterload and preload)
• Contractility (inotropy)

• Rises progressively from resting level (~70 bpm) with increasing exercise intensity
• Driven by: increased sympathetic activity (+β₁ stimulation), withdrawal of parasympathetic (vagal) tone
• At sub-maximal exercise: HR typically reaches 100-140 bpm depending on intensity and fitness
• Formula for predicted maximum HR: HRmax = 220 - age (years)
• Sub-maximal target = 70-85% of HRmax

• Systolic BP rises significantly with exercise (due to increased cardiac output and sympathetic vasoconstriction in non-exercising vascular beds)
• Diastolic BP remains relatively unchanged or slightly decreases (due to marked vasodilation in exercising skeletal muscle - β₂ mediated)
• Pulse pressure increases (systolic rises, diastolic unchanged or falls)

SECTION 4: PROPRANOLOL - PHARMACOLOGY

• Propranolol, timolol, nadolol, sotalol, pindolol (ISA), carteolol

• Atenolol, metoprolol, bisoprolol, acebutolol (ISA), nebivolol (also β₃/NO-mediated vasodilation)

• Labetalol (β₁ + β₂ + α₁ blockade)
• Carvedilol (β₁ + β₂ + α₁ blockade)
• Nebivolol (β₁ selective + β₃ agonism + nitric oxide release)

• ISA (Intrinsic Sympathomimetic Activity): Pindolol, acebutolol (partial agonists - cause less bradycardia)
• Lipophilicity: Propranolol = highly lipophilic (enters CNS); Atenolol = hydrophilic (less CNS effects)
• MSA (Membrane Stabilizing Activity): Propranolol, acebutolol (quinidine-like Na⁺ channel blocking at high doses)

1. Immediate (cardiac): ↓HR (negative chronotropy) and ↓inotropy → ↓cardiac output → ↓BP
2. Delayed (renal): ↓renin secretion → ↓Angiotensin II → ↓aldosterone → ↓sodium/water retention → ↓blood volume → ↓BP
3. CNS: Lipophilic propranolol enters CNS → reduces central sympathetic outflow → ↓BP
4. Prejunctional: Blocks prejunctional β₂ receptors on sympathetic nerve terminals → reduces noradrenaline release (minor contribution)

• If current (Funny/HCN channels): Carries Na⁺ inward during diastole (phase 4 depolarization) - the primary pacemaker current
• ICa-L (L-type Ca²⁺ channels): Upstroke (phase 0) in nodal cells
• Sympathetic β₁ stimulation activates adenylyl cyclase → ↑cAMP → PKA → phosphorylates HCN channels → accelerates If → faster Phase 4 slope → increased HR (positive chronotropy)

• At rest: Modest reduction (5-15 bpm), because basal sympathetic tone is low
• Post-exercise: Pronounced reduction - exercise markedly increases sympathetic tone; propranolol blocks the exercise-induced tachycardia; blunts the rise in HR during and after exercise
• Expected: Post-exercise HR significantly lower with propranolol than placebo

• At rest: Mild reduction
• Post-exercise: Significant blunting of the exercise-induced rise in SBP (reduced cardiac output + reduced contractile force)
• Diastolic BP: variable; may slightly increase initially (β₂ blockade removes vasodilatory tone) but then normalizes

• Significantly reduced post-exercise with propranolol vs. placebo
• This is the most important endpoint: demonstrates that propranolol reduces myocardial oxygen demand during exertion
• Clinically translates to: propranolol raises the threshold at which angina occurs in coronary artery disease patients

• Propranolol competitively blocks β₁ receptors; at rest, sympathetic tone is low (endogenous noradrenaline concentrations are low), so propranolol occupies receptors but there is minimal competition from the agonist
• During exercise, plasma catecholamines (noradrenaline, adrenaline) surge massively → flood β₁ receptors
• Propranolol must competitively overcome this increased agonist concentration - some breakthrough occurs, but the net blockade still substantially limits the full tachycardic response
• The difference (delta) between drug and placebo HR is greatest at peak exercise, demonstrating the state-dependent nature of beta-blocker pharmacodynamics
• This is also why propranolol cannot completely abolish exercise-induced tachycardia but still significantly blunts it

SECTION 5: CARDIOVASCULAR PHYSIOLOGY

• Muscle mechanoreceptors (Group III Aδ fibers) and metaboreceptors (Group IV C fibers) sense mechanical activity and metabolites (K⁺, H⁺, lactate) → signal to cardiovascular centers → ↑sympathetic output

• Heart (β₁): ↑HR (chronotropy), ↑contractility (inotropy), ↑conduction velocity (dromotropy), ↑automaticity (bathmotropy)
• Arterioles in exercising muscle: β₂ receptors → vasodilation (+ local metabolic vasodilation)
• Arterioles in non-exercising tissues (splanchnic, renal, skin): α₁ receptors → vasoconstriction → redirects blood flow to exercising muscles
• Veins: α₁ → venoconstriction → ↑venous return → ↑preload → ↑stroke volume (Starling)
• Adrenal medulla: releases adrenaline and noradrenaline → systemic catecholamine surge

• During exercise, increased venous return augments stroke volume via Starling mechanism
• Propranolol reduces contractility (negative inotropy via β₁ blockade) → partially blunts the Starling-mediated increase in stroke volume
• However, propranolol does not abolish the Starling response (which is independent of β-adrenoceptors at the cellular level) - contractility is reduced but the muscle can still respond to increased stretch
• In heart failure patients, chronic beta-blocker therapy (e.g., carvedilol) paradoxically improves EF over time by reversing catecholamine-induced cardiac remodeling - this is distinct from the acute negative inotropic effect

Wall Tension (T) = Pressure (P) × Radius (r) / (2 × wall thickness)

• Wall tension = the force the myocardium must generate to maintain a given intraventricular pressure
• Pressure = systolic ventricular pressure (≈ systolic BP/afterload)
• Radius = ventricular end-diastolic radius (= preload)

• ↑Afterload (↑SBP) → ↑wall tension → ↑myocardial oxygen demand
• ↑Preload (↑EDV/radius) → ↑wall tension → ↑O₂ demand (partially offset by increased contractility)
• ↑HR → less diastolic filling time → shorter diastole → reduced coronary perfusion + increased MVO₂

• HR (→ ↑diastolic coronary perfusion time + ↓MVO₂)
• SBP (→ ↓afterload → ↓wall tension → ↓MVO₂)
• Inotropy (→ ↓O₂ demand per beat)

Blood Pressure (BP) = Cardiac Output (CO) × Total Peripheral Resistance (TPR) CO = Heart Rate (HR) × Stroke Volume (SV)

SECTION 6: CLINICAL PHARMACOLOGY OF PROPRANOLOL

• Hypertension (not first-line now; first-line for young patients with high sympathetic tone, or with co-morbid conditions below)
• Angina pectoris (stable angina - reduces frequency and severity of anginal attacks by ↓cardiac workload)
• Cardiac arrhythmias - SVT, atrial fibrillation/flutter (rate control), AV nodal re-entry tachycardia, ventricular tachycardia (catecholamine-induced)
• Post-myocardial infarction (secondary prevention - reduces reinfarction and mortality)
• Hypertrophic obstructive cardiomyopathy (HOCM) - reduces outflow obstruction
• Aortic dissection (with sodium nitroprusside - reduces pulsatile aortic pressure)

• Hyperthyroidism / thyrotoxicosis - controls tachycardia, tremor, anxiety while awaiting definitive therapy; blocks peripheral T₄→T₃ conversion
• Migraine prophylaxis (mechanism unclear - may reduce neuronal excitability, vasomotor events)
• Essential tremor (β₂ blockade reduces tremor in peripheral muscles)
• Anxiety / situational performance anxiety (controls peripheral manifestations: palpitations, tremor)
• Pheochromocytoma (only after alpha-blocker is established first - to control tachycardia after alpha-blockade)
• Portal hypertension - reduces portal venous pressure; prevents variceal re-bleeding

• Bronchial asthma / severe COPD - β₂ blockade causes bronchoconstriction; life-threatening
• Decompensated heart failure - acute negative inotropy worsens pump failure (chronic heart failure may use cardioselective beta-blockers carefully under supervision)
• Sick sinus syndrome / high-degree AV block (without pacemaker) - propranolol slows SA node and AV conduction
• Hypotension / cardiogenic shock - reduces CO further
• Severe bradycardia (HR < 50 bpm)

• Prinzmetal's (vasospastic) angina - β₂ blockade unmasks α-adrenergic coronary vasoconstriction → may worsen spasm
• Diabetes mellitus - masks hypoglycemic symptoms (except sweating); inhibits glycogenolysis
• Peripheral vascular disease / Raynaud's phenomenon - β₂ blockade causes vasoconstriction → worsens claudication
• Pheochromocytoma without prior alpha-blockade - may precipitate hypertensive crisis
• Pregnancy (relative) - fetal bradycardia, IUGR

• Bradycardia, AV block, heart failure precipitation
• Cold extremities (β₂ blockade → peripheral vasoconstriction)

• Bronchoconstriction (β₂ blockade) - dangerous in asthmatics

• Impairs glycogenolysis (delays recovery from hypoglycemia) - problematic in insulin-dependent diabetics
• Masks hypoglycemic tachycardia
• Dyslipidemia: ↑triglycerides, ↓HDL

• Fatigue, depression, nightmares/vivid dreams, sleep disturbances, hallucinations
• Sexual dysfunction

• Upregulation of β-adrenoceptors during chronic therapy → abrupt discontinuation causes rebound tachycardia, hypertension, angina, and risk of MI ("beta-blocker withdrawal syndrome")
• Must be tapered gradually over 1-2 weeks

• Masking of hyperthyroidism symptoms (during thyrotoxicosis management)
• Raynaud's phenomenon

• Causes less bradycardia at rest (the partial agonist effect maintains a baseline HR)
• Less cold extremities and bronchospasm than propranolol
• Propranolol has NO ISA - it is a pure competitive antagonist
• Drugs with ISA may not be as effective as pure antagonists for post-MI protection

• Contributes to anti-arrhythmic activity (Class II antiarrhythmic by beta-blockade; MSA adds a Class I-like membrane stabilizing effect at higher doses)
• MSA is only seen at supra-therapeutic doses and has limited clinical relevance at standard doses
• In overdose toxicity, MSA causes dangerous QRS widening and ventricular arrhythmias

SECTION 7: STUDY DESIGN AND ETHICS

• Session 1: Volunteer receives propranolol (40-80 mg oral) OR matching placebo → 60-90 min later → Master's Two-Step Test → HR and BP recorded pre/post-exercise
• Washout period: Minimum 5 × t½ = 5 × 4 hrs = ~48-72 hours (some protocols use 1 week)
• Session 2: Volunteer receives the other treatment (crossover) → same procedure
• Randomization sequence determined by sealed envelopes or random number table
• Both volunteer and investigator blinded until after data collection (double-blind)

• Healthy adults, 18-40 years
• Normal resting ECG
• Normal baseline HR (60-100 bpm) and BP (120/80 ± range)
• Normal exercise capacity (can complete the Two-Step test)
• Written informed consent

• Bronchial asthma or COPD (β₂ blockade hazard)
• Cardiac arrhythmias, AV block, or sick sinus syndrome
• Hypertension requiring treatment
• Diabetes mellitus (masking of hypoglycemia)
• Peripheral vascular disease
• Current use of antihypertensives, beta-blockers, or other cardiovascular drugs
• Athletes with baseline bradycardia (HR < 50 bpm)
• Pregnancy
• Known hypersensitivity to propranolol
• Musculoskeletal conditions preventing step exercise

• Written informed consent covering propranolol's effects, potential adverse effects (bradycardia, bronchospasm), and exercise-related risks
• IEC/IRB approval
• Compliance with Declaration of Helsinki and ICMR guidelines (India)
• Physician present during all exercise sessions
• Emergency medications available: atropine (for severe bradycardia), bronchodilator (salbutamol inhaler), and basic resuscitation equipment
• Pre-defined stopping criteria: HR < 40 bpm, SBP > 200 mmHg, severe dyspnea, chest pain, ECG changes (if monitored)
• Adequate washout between sessions to prevent carryover
• Right to withdraw without penalty at any time

SECTION 8: RESULTS AND INTERPRETATION

• Paired t-test: Compare propranolol vs. placebo sessions (paired because same volunteer is in both sessions)
• Repeated measures ANOVA: For multiple time-point comparisons (resting, immediately post-exercise, 5 min recovery, 10 min recovery)
• Results expressed as mean ± SEM
• p < 0.05 = statistically significant

• Sympathetic-driven recovery (catecholamine-mediated rebound tachycardia) is blunted by beta-blockade
• This is actually a disadvantage in healthy people (exercise tolerance reduced) but a clinical advantage in angina patients (avoids post-exercise angina)
• Prolonged recovery time also indicates that propranolol is still pharmacologically active during the recovery phase, confirming its duration of action

SECTION 9: BROADER PHARMACOLOGICAL CONTEXT

• Beta-blockers prevent reflex tachycardia caused by nitrates
• Nitrates reduce preload (venodilation) + afterload (arterial dilation), complementing beta-blocker's HR/inotropy reduction
• Together they provide superior anti-anginal effect than either alone

1. Cardioselective β₁ blockers (metoprolol, bisoprolol, atenolol) - at LOW doses, they preferentially block β₁ without significant β₂ blockade; use with caution, not absolute safety in severe asthma
2. Calcium channel blockers (amlodipine for hypertension; verapamil/diltiazem for angina and rate control)
3. Ivabradine (If channel blocker - reduces HR without β₂ effects, for angina)
4. Nitrates (for angina)
5. Note: No beta-blocker is completely safe in severe asthma; even cardioselective agents lose selectivity at higher doses

1. Angina pectoris management: Propranolol reduces RPP (cardiac workload) during exercise → raises the threshold at which ischemia/angina occurs in CAD patients → decreases frequency and severity of anginal episodes
2. Hypertension treatment: Demonstrates propranolol's antihypertensive effect, especially during sympathetically activated states (stress, exercise)
3. Heart rate control: Validates propranolol's use for rate control in atrial fibrillation/flutter during exercise
4. Exercise tolerance in cardiac rehabilitation: Establishes safe exercise heart rate targets for patients on beta-blockers (target HR calculation must be adjusted; cannot use standard 220-age formula)
5. Drug development: Model for testing newer beta-blockers (cardioselective, vasodilatory) and comparing their effects on exercise-induced cardiac workload vs. propranolol
6. Thyrotoxicosis: Similar mechanism explains propranolol's benefit in controlling exercise-related tachycardia in thyroid storm